Search

Your search keyword '"Andronis, Lazaros"' showing total 208 results

Search Constraints

Start Over You searched for: Author "Andronis, Lazaros" Remove constraint Author: "Andronis, Lazaros"
208 results on '"Andronis, Lazaros"'

Search Results

7. Bio-impedance spectroscopy added to a fluid management protocol does not improve preservation of residual kidney function in incident hemodialysis patients in a randomized controlled trial

10. Health-related quality of life at 5 years of age for children born very preterm with congenital anomalies: a multi-national cohort study

11. Cardiac prehabilitation, rehabilitation and education in first-time atrial fibrillation (AF) ablation (CREED AF): Study protocol for a randomised controlled trial.

12. Variation in follow-up for children born very preterm in Europe

14. Analytic approaches for informing research funding decisions : an exploration of their role and value using case studies of cancer clinical trials

16. The PLANES study: a protocol for a randomised controlled feasibility study of the placental growth factor (PlGF) blood test-informed care versus standard care alone for women with a small for gestational age fetus at or after 32 + 0 weeks’ gestation

20. Variation in follow-up for children born very preterm in Europe.

24. Health-related quality of life of children born very preterm : a multinational European cohort study

27. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial

28. REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy study

31. Follow-up after very preterm birth in Europe

33. Are acceptance and mindfulness‐based interventions ‘value for money’? Evidence from a systematic literature review

34. Validation of the Bluebelle Wound Healing questionnaire (WHQ) for assessment of surgical site infection in primary surgical wounds after hospital discharge

35. Additional file 8: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

36. Additional file 1: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

37. Additional file 7: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

38. Additional file 4: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

39. Additional file 3: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

40. Additional file 2: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

41. Additional file 5: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

42. Additional file 6: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

43. Three wound-dressing strategies to reduce surgical site infection after abdominal surgery: the Bluebelle feasibility study and pilot RCT

44. Participants' preference for type of leaflet used to feed back the results of a randomised trial: a survey

45. Developing outcome measures assessing wound management and patient experience: a mixed methods study

47. Micronutrient deficiencies and health-related quality of life: the case of children with vitamin D deficiency.

Catalog

Books, media, physical & digital resources